← All indications
Pemphigus
Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS.
Drugs by status
Approved for this indication (4)
Phase 4 trials (5)
Phase 3 trials (10)
Phase 2 trials (14)
Phase 1 trials (8)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (25)
- Incyte
- Jacobus Pharmaceutical
- Kemia, Inc
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pennsylvania
- Central South University
- Case Western Reserve University
- Harvard University
- Duke University
- Florida Academic Dermatology Centers
- Johns Hopkins University
- New York University
- Northwestern University
- Stanford University
- University of Iowa
- University of Southern California
- University of California, Los Angeles
- University of California, San Francisco
- Isfahan University
- Rush University
- University of Lubeck
- The University of Hong Kong
- University of North Carolina at Chapel Hill
- Rowan University
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (2)